NKGen Biotech

NKGen Biotech Cash Conversion Cycle

The Cash Conversion Cycle (CCC) of NKGen Biotech (NKGN) as of Nov 22, 2026 is -3,425.48. In the previous year, Cash Conversion Cycle (CCC) was -17,073.89 — a change of -79.94% (higher).

Cash Conversion Cycle

-3,425.48

YoY

-79.94%

Last updated:

Cash Conversion Cycle (CCC) of NKGen Biotech is 2023 -3,425.48 . Cash Conversion Cycle (CCC) of NKGen Biotech was 2022 -17,073.89 . It decreases by -79.94% higher compared to the previous year.

The NKGen Biotech Cash Conversion Cycle history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Cash Conversion Cycle
Date
Cash Conversion Cycle
Jan 1, 2021
-18,761.00 USD
Jan 1, 2022
-17,073.89 USD
Jan 1, 2023
-3,425.48 USD
The NKGen Biotech Cash Conversion Cycle history
YEARCash Conversion CycleYoY
-3,425.48-79.94%
-17,073.89-8.99%
-18,761.00—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

NKGen Biotech Stock analysis

What does NKGen Biotech do? NKGen Biotech Inc develops autologous and allogeneic NK cell therapies for neurodegenerative and oncological diseases using its SuperNK platform. The company commercializes SNK01 for neurodegenerative diseases and SNK02 for cancer through clinical trials. Autologous NK cell immunotherapy involves harvesting pure NK cells from patients, activating them, and reinfusing them to enhance immune function and eliminate abnormal cells. The company focuses on treating cancer and neurodegenerative conditions with its SNK platform therapies. NKGen Biotech Inc's revenue model is based on conducting clinical trials for SNK01 and SNK02, with potential future commercialization of these therapies. The company is clinical-stage, meaning it generates income through research and development funding rather than product sales. Its primary focus is on developing therapies for cancer and neurodegenerative diseases using autologous and allogeneic NK cell approaches. The company's SNK platform enables the development of therapies that use pure NK cells harvested from patients' blood, activated, and reinfused to improve immune system function. This approach targets cancer, autoimmune, and neurodegenerative diseases. NKGen Biotech Inc's business model centers on advancing these therapies through clinical trials to reach commercialization stage. NKGen Biotech is one of the most popular companies on Eulerpool.

Frequently Asked Questions about NKGen Biotech stock

Cash Conversion Cycle (CCC) of NKGen Biotech is -3,425.48 in 2023.

Cash Conversion Cycle (CCC) of NKGen Biotech changed from -17,073.89 to -3,425.48, representing a -79.94% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Cash Conversion Cycle (CCC) NKGen Biotech since 2006 – with annual values, charts, and detailed analysis.

The Cash Conversion Cycle measures how long it takes to convert inventory investments into cash from sales. A shorter CCC indicates more efficient working capital management.

CCC = DSO + DIO - DPO

A 'good' varies by industry and company stage. On Eulerpool, you can compare Cash Conversion Cycle (CCC)'s NKGen Biotech with sector peers and the industry average to assess whether it is attractive.

To evaluate Cash Conversion Cycle (CCC)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Cash Conversion Cycle (CCC).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — NKGen Biotech

All Key Metrics — NKGen Biotech